Comments
Cadila Healthcare has received five observations from USFDA after the inspection of Liva Pharmaceuticals’ injectables manufacturing facility. Liva is a 100 per cent subsidiary of Cadila Healthcare.
“This was a product specific pre-approval inspection. It concluded with 5 observations. Liva will respond to USFDA within 15 days. It may be noted that at present Liva does not export any products to the US market,” Cadila Healthcare said in a filing to the BSE today.
The injectables facility is located at Vadodara. The United States Food and Drug Administration (USFDA) had conducted the inspection from August 20-28. Shares of Cadila Healthcare ended down by 2.45 per cent at Rs 386.75 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.